The value of serial ANCA testing during follow-up studies in patients with ANCA-associated vasculitides. A review

Journal of Nephrology

Volumn 9, Issue 5, 1996, Pages 232-240

  Cohen Tervaert, Jan Willem ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA; glomerulonephritis; myeloperoxidase; proteinase 3; relapse; vasculitis; Wegener's granulomatosis

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE;

GLOMERULONEPHRITIS; HUMAN; REVIEW; VASCULITIS; WEGENER GRANULOMATOSIS;

EID: 0029903664     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (91)

1. Alarcón-Segovia D. Classification of the necrotizing vasculitides in man. Clin Rheum Dis 1980; 6: 223-31.
2. Lie JT. Vasculitis, 1815 to 1991: classification and diagnostic specificity. J Rheumatol 1992; 19: 83-9.
3. Lie JT. Nomenclature and classification of vasculitis: plus ca change, plus c'est la meme chose. Arthritis Rheum 1994; 37: 181-6.
4. Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, et al. The American College of rheumatology 1990 criteria for the classification of vasculitis. Arthritis Rheum 1990; 33: 1065-136.
5. Jennette JC, Falk RJ, Andrassy K, Bacon BA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: the proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
6. Jennette JC, Wilkman AS, Falk RJ. Antineutrophil cytoplasmic autoantibodies-associated glomerulonephritis and vasculitis. Am J Pathol 1989; 135: 921-30.
7. Cohen Tervaert JW, Goldschmeding R, Elema JD, van der Giessen M, Huitema MG, van der Hem GK, von dem Borne AEGKr, Kallenberg CGM. Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. Kidney Int 1990; 37: 799-806.
8. Haynes BF. Vasculitis: pathogenic mechanisms of vessel damage. In: Gallin JI, Goldstein IM, Snyderman R, eds. Inflammation: basic principles and clinical correlates, 2nd ed. New York: Raven Press 1992; 921-41.
9. Savage COS, Ng YC. The aetiology and pathogenesis of major systemic vasculitides. Postgrad Med J 1986; 62: 627-36.
10. Kallenberg CGM, Cohen Tervaert JW, van der Woude FJ, Goldschmeding R, von dem Borne AEGKr, Weening JJ. Autoimmunity to lysosomal enzymes: new clues to vasculitis and glomerulonephritis? Immunol Today 1991; 12: 61-4.
11. Cotran RS, Pober JS. Recent insights into mechanisms of vascular injury. Implications for the pathogenesis of vasculitis. In: Simionescu N, Simionescu M, eds. Endothelial cell dysfunctions. New York: Plenum Press 1992; 183-9.
12. Cohen Tervaert JW, Kallenberg CGM. The role of autoimmunity to myeloid lysosomal enzymes in the pathogenesis of vasculitis. In: Hansson GK, Libby P, eds. Immune functions of the vessel wall. In press.
13. Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994; 46: 1-15.
14. Kallenberg CGM, Brouwer E, Mulder AHL, Stegeman CA, Weening JJ, Cohen Tervaert JW. ANCA-pathophysiology revisited. Review. Clin Exp Immunol 1995; 100: 1-3.
15. Gross WL, Csernok E. Immunodiagnostic and pathophysiologic aspects of antineutrophil cytoplasmic antibodies in vasculitis. Curr Opin Rheumatol 1995; 7: 11-9.
16. Proceedings of the 6th International ANCA Workshop. Clin Exp Immunol 1995; 101 (suppl 1): 1-78.
17. Davies DJ, Moran JE, Niall JF, Ryan GB. Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J 1982; 285: 606.
18. Van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, van Es LA, van der Giessen M, van der Hem, The TH. Autoantibodies to neutrophils and monocytes: a new tool for diagnosis and a marker of disease activity in Wegener's granulomatosis. Lancet 1985; ii: 425-9.
19. Savage COS, Winearls CG, Jones SJ, Marshall PD, Lockwood CM. Prospective study of radioimmunoassay for antibodies against neutrophil cytoplasm in diagnosis of systemic vasculitis. Lancet 1987; 8: 1389-93.
20. Cohen Tervaert JW, Goldschmeding R, Elema JD, von dem Borne AEGKr, Kallenberg CGM. Anti-myeloperoxidase antibodies in the Churg Strauss Syndrome. Thorax 1991; 46: 70-1.
21. Kallenberg CGM, Mulder AHL, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: a still-growing class of autoantibodies in inflammatory disorders. Am J Med 1992; 93: 675-82.
22. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. APMIS 1989; 97 (S6): 12-3.
23. Goldschmeding R, van der School CE, ten Bokkel Huinink D, Hack CE, van den Ende E, Kallenberg CGM, von dem Borne AEGKr. Wegener's granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989; 84: 1577-87.
24. Niles JL, McCluskey RT, Ahmad MF, Arnaout MA. Wegener's granulomatosis autoantigen is a novel serine proteinase. Blood 1989; 74: 1888-93.
25. Lüdemann J, Utecht B, Gross WL. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med 1990; 171: 357-62.
26. Cohen Tervaert JW. Detection and clinical associations of autoantibodies to myeloid granular proteins. Adv Exp Med Biol 1993; 336: 299-302.
27. Goldschmeding R, Cohen Tervaert JW, van der School CE, van der Veen C, Kallenberg CGM, von dem Borne AEGKr. ANCA, anti-myeloperoxydase and anti-elastase: three members of a novel class of autoantibodies against myeloid lysosomal enzymes. APMIS 1989; 97 (S6): 48-9.
28. Cohen Tervaert JW, Goldschmeding R, Elema JD, van der Giessen M, Huitema MG, Koolen MI, Hene RJ, The TH, van der Hem GK, von dem Borne AEGKr, Kallenberg CGM. Association of autoantibodies to myeloperoxidase with different forms of vasculitis. Arthritis Rheum 1990; 33: 1264-72.
29. Cohen Tervaert JW, Limburg PC, Elema JD, Huitema MG, Horst G, The TH, Kallenberg CGM. Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med 1991; 91: 59-66.
30. Roozendaal C, Pogány K, Horst G, Kleibeuker JH, Nelis GF, Limburg PC, Kallenberg CGM. Prevalence and characterization of ANCA in inflammatory bowel disease (abstract). Sarcoidosis: in press.
31. Roozendaal C, Horst G, Haagsma EB, Horst G, Haagsma EB, Schwartze C, Peter HH, Berg P, Cohen Tervaert JW, Limburg PC, Kallenberg CGM. Bactericidal/permeability-increasing protein is a major ANCA antigen in primary sclerosing cholangitis (abstract). Sarcoidosis: in press.
32. Niles JL, Pan G, Collins AB, Shannon T, Skates S, Fienberg R, Arnaout MA, McCluskey RT. Antigen-specific radioimmunoassays for anti-neutrophil cytoplasmic antibodies in the diagnosis of rapidly progressive glomerulonephritis. J Am Soc Nephrol 1991; 2: 27-36.
33. Cohen Tervaert JW, van der Woude FJ, Fauci AS, Ambrus JL, Velosa J, Keane WF, Meijer S, van der Giessen M, The TH, van der Hem GK, Kallenberg CGM. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Int Med 1989; 149: 2461-5.
34. Nölle B, Specks V, Lüdemann J, Rohrbach MS, De Remee DA, Gross WL. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener's granulomatosis. Ann Int Med 1989; 111: 28-40.
35. Kallenberg CGM, Cohen Tervaert JW. Anti-neutrophilic cytoplasmic antibodies: new tools in the diagnosis and follow-up of necrotizing glomerulonephritis. In: Andreucci VE, Fine LG, eds. International Yearbook of Nephrology 1992. London: Springer-Verlag 1991; 313-35.
36. Gaskin G, Savage COS, Ryan JJ, et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991; 6: 689-94.
37. Geffriaud-Ricouard C, Noël LH, Chauveau D, Houhou S, Grünfeld JP, Lesavre P. Clinical spectrum associated with ANCA of defined antigen specificities in 98 selected patients. Clin Nephrol 1993; 39: 125-36.
38. Hagen EC. Development and standardization of solid-phase assays for the detection of anti-neutrophil cytoplasmic antibodies for clinical application: report of a large clinical evaluation study. Clin Exp Immunol 1995; 101 (S1): 29.
39. Bosch X, Mirapeix E, Font J, et al. Anti-myeloperoxidase autoantibodies in patients with necrotizing glomerular and alveolar capillaritis. Am J Kidney Dis 1992; 20: 231-9.
40. Cohen P, Guillevin L, Baril L, Lhote F, Noel LH, Lesavre P. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. Clin Exp Rheumatol 1995; 13: 193-8.
41. Spronk P, Horst G, Huitema MG, Limburg PC, Cohen Tervaert JW, Kallenberg CGM. Anti neutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 625-31.
42. Cambridge G, Williams M, Leaker B, Corbett M, Smith CR. Anti-myeloperoxidase antibodies in patients with rheumatoid arthritis: prevalence, clinical correlates, and IgG subclass. Ann Rheum Dis 1994; 53: 24-9.
43. Endo H, Hosono T, Kondo H. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheumatol 1994; 21: 864-70.
44. Dolman KM, Gans ROB, Vervaart THJ, Zevenbergen G, Maingay D, Nikkels RE, Donker AJM, Von Dem Borne AEGKr, Goldschmeding R. Vasculitic disorders and anti-neutropbil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993; 342: 651-2.
45. Cohen Tervaert JW, Tel W, De Vries O, Links TP, Stegeman CA. The occurrence of anti-neutrophil cytoplasmic antibodies (ANCA) with specificity for proteinase 3, myeloperoxidase, and/or elastase during treatment with antithyroid drugs (abstract). Sarcoidosis: in press.
46. Nāssberger L, Johansson A-C, Bjōrck S, Sjōholm AG. Antibodies to neutrophil granulocyte myeloperoxidase and elastase: autoimmune responses in glomerulonephritis due to hydralazine treatment. J Int Med 1991; 229: 261-5.
47. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann Int Med 1994; 120: 12-7.
48. Stegeman CA, Cohen Tervaert JW, Mulder AHL, Huitema MG, Limburg PC, de Jong PE, Kallenberg CGM. Levels of the IgG3 subclass of ANCA directed against proteinase 3 are related to disease activity in patients with Wegener's granulomatosis. In: Stegeman CA. Wegener's granulomatosis: immunological and microbiological factors involved in disease activation. PhD Thesis. University of Groningen, Groningen 1995; 37-55.
49. Franssen CFM, Stegeman CA, Oost-Kort W, Kallenberg CGM, Cohen Tervaert JW. Persistently high levels of antibodies to myeloperoxidase (MPO) are predictive of poor renal outcome in patients with anti-MPO associated glomerulonephritis (abstract). Sarcoidosis: in press.
50. Jayne DRW, Gaskin G, Pusey CD, Lockwood CM. ANCA and predicting relapse in systemic vasculitis. Q J Med 1995; 88: 127-33.
51. de'Oliviera J, Gaskin G, Dash A, Rees AJ, Pusey CD. Relationship between disease activity and anti-neutrophil cytoplasmic antibody concentration in long-term management of systemic vasculitis. Am J Kidney Dis 1995; 25: 380-9.
52. Power WJ, Rodriguez A, Neves RA, Lane L, Foster S. Disease relapse in patients with ocular manifestations of Wegener granulomatosis. Ophthalmology 1995; 102: 154-60.
53. Cohen Tervaert JW, Huitema MG, Hene RJ, Sluiter WJ, The Th, van der Hem GK, Kallenberg CGM. Prevention of relapses of Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-11.
54. Specks U, Wheatley CL, McDonald TJ, Rohrbach MS, De Remee RA. Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. Mayo Clin Proc 1989; 64: 28-36.
55. Egner W, Chapel HM. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol 1990; 82: 244-9.
56. Halma C, Daha MR, Schrama E, Hermans J, van Es LA, van der Woude FJ. Value of anti-neutrophil cytoplasmic autoantibodies and other laboratory parameters in follow-up of vasculitis. Scand J Rheumatology 1990; 19: 392-7.
57. Pettersson E, Heigl Z. Antineutrophil cytoplasmic antibody (cANCA and pANCA) titers in relation to disease activity in patients with necrotizing vasculitis: a longitudinal study. Clin Nephrol 1992; 37: 219-28.
58. Chan TM, Frampton G, Jayne DRW, Perry GJ, Lockwood CM, Cameron JS. Clinical significance of anti-endothelial cell antibodies in systemic vasculitis: a longitudinal study comparing anti-endothelial cell antibodies and anti-neutrophil cytoplasm antibodies. Am J Kidney Dis 1993; 22: 387-92.
59. Kerr GS, Fleisher TA, Hallahan CW, Leavitt RY, Fauci AS, Hoffman GS. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener's granulomatosis. Arthritis Rheum 1993; 36: 365-71.
60. Davenport A, Lock RJ, Wallington T. Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test. Am J Nephrol 1995; 15: 201-7.
61. Cohen Tervaert JW, Mulder AHL, Kallenberg CGM, Stegeman CA. Measurement of IgG3 levels of anti-proteinase 3 antibodies is useful in monitoring disease activity in Wegener's granulomatosis (abstract). J Am Soc Nephrol 1994; 5: 828.
62. Mulder AHL, Stegeman CA, Kallenberg CGM. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: a predominant role for the IgGS subclass of ANCA. Clin Exp Immunol 1995; 101: 227-32.
63. Wiel A van de, Dolman KM, van der Meer-Gerritsen CH, Hack CE, von dem Borne AEGKr, Goldschmeding R. Interference of Wegener's granulomatosis autoantibodies with neutrophil proteinase 3 activity. Clin Exp Immunol 1992; 90: 409-14.
64. Dolman KM, Stegeman CA, van de Wiel BA, Hack CE, von dem Borne AEGKr, Kallenberg CGM, Goldschmeding R. Relevance of classic anti-neutrophil cytoplasmic autoantibody (c-ANCA)-mediated inhibition of proteinase 3-α1-antitrypsin complexation to disease activity in Wegener's granulomatosis. Clin Exp Immunol 1993; 93: 405-10.
65. Daouk GH, Palsson R, Arnaout MA. Inhibition of proteinase 3 by ANCA and its correlation with disease activity in Wegener's granulomatosis. Kidney Int 1995; 47: 1528-36.
66. Jayne DRW, Weetman AP, Lockwood CM. IgG subclass distribution of autoantibodies to neutrophil cytoplasmic antigens in systemic vasculitis. Clin Exp Immunol 1991; 84: 476-81.
67. Esnault VLM, Jayne DRW, Weetman AP, Lockwood CM. IgG subclass distribution and relative functional affinity of antimyeloperoxidase antibodies in systemic vasculitis at presentation and during follow-up. Immunology 1991; 74: 714-8.
68. Brouwer E, Cohen Tervaert JW, Horst G, Huitema MG, van der Giessen M, Limburg PC, Kallenberg CGM. Predominance of IgG1 and IgG4 subclass of antineutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders. Clin Exp Immunol 1991; 83: 379-86.
69. Williams RC Jr, Staud R, Malone C, Payabyab J, Byres L, Underwood D. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J Immunology 1994; 152: 4722-37.
70. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87: 4115-9.
71. Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992; 41: 375-83.
72. Savage COS, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity towards cultured endothelial cells. Am J Pathol 1992; 141: 335-42.
73. Charles LA, Caldas MLR, Falk RJ, Terrell RS, Jennette JC. Antibodies against granule proteins activate neutrophils in vitro. J Leukocyte Biol 1991; 50: 539-46.
74. Csernok E, Ernst M, Schmitt WH, Bainton DF, Gross WL. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin Exp Immunol 1994; 95: 244-50.
75. Muller Kobold AC, Mesander C, Kallenberg CGM, Cohen Tervaert JW. Activated circulating neutrophils in relation to disease activity in ANCA-associated vasculitis (abstract). Clin Exp Immunol 1995; 101: 57.
76. Porges AJ, Redecha PB, Csernok E, Gross WL, Kimberly RP. Monoclonal ANCA (anti-MPO and anti-Pr3) engage and activate neutrophils via Fcr Receptor IIA. J Immunol 1994; 153: 1271-80.
77. Mulder AHL, Horst G, Limburg PC, Kallenberg CGM. Activation of neutrophils by anti-neutrophil cytoplasmic antibodies is FcR-dependent. Clin Exp Immunol 1994; 98: 270-8.
78. Mayet WJ, Meyer Zum Büschenfelde KH. Antibodies to proteinase 3 increase adhesion of neutrophils to human endothelial cells. Clin Exp Immunol 1993; 94: 440-6.
79. Mayet W-J, Schwarting A, Orth T, Duchman R, Meyer zum Būschenfelde K-H. Antibodies to proteinase 3 mediate expression of vascular cell adhesion molecule-1 (VCAM-1). Clin Exp Immunol 1996; 103: 259-67.
80. Kobayashi K, Shibata T, Sugisaki T. Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies. Kidney Int 1995; 47: 454-63.
81. Brouwer E, Huitema MG, Klok PA, Weerd H de, Cohen Tervaert JW, Weening JJ, Kallenberg CGM. Anti-myeloperoxidase-associated proliferative glomerulonephritis: an animal model. J Exp Med 1993; 177: 905-14.
82. Gaskin G, Pusey CD. Systemic vasculitis. In: Cameron JS, Davison AM, Grünfeld J, Kerr DNS, Ritz E, eds. Oxford Textbook of clinical nephrology. Oxford: Oxford University Press 1992; 612-36.
83. Balow JE, Fauci AS. Vasculitic diseases of the kidney: polyarteritis, Wegener's granulomatosis, necrotizing and crescentic glomerulonephritis, and other disorders. In: Schrier RW, Gottschalk CW, eds. Diseases of the kidney. 5th Edition. Boston: Little, Brown and Company 1993; 2095-117.
84. Walton EW. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br Med J 1958; 2: 265-70.
85. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85.
86. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener's granulomatosis: an analysis of 158 patients. Ann Int Med 1992; 116: 488-98.
87. Cohen J, Pinching AJ, Rees AJ, Peters DK. Infection and immunosuppression: a study of the infective complications of 75 patients with immunologically mediated disease. Q J Med 1982; 51: 1-15.
88. Bradley JD, Brandt KD, Katz BP. Infectious complications of cyclophosphamide treatment for vasculitis. Arthritis Rheum 1989; 32: 45-53.
89. Stillwell TJ, Benson RC, DeRemee RA, McDonald TJ, Weiland LH. Cyclophosphamide-induced bladder toxicity in Wegener's granulomatosis. Arthritis Rheum 1988; 31: 465-70.
90. Hoffman GS, Leavitt RY, Fleisher TA, Minor JR, Fauci AS. Treatment of Wegener's granulomatosis with intermittent high-dose intravenous cyclophosphamide. Am J Med 1990; 89: 403-10.
91. Rasmussen N, Jayne DRW, Abramowicz D, et al. European therapeutic trials in ANCA-associated systemic vasculitis: disease scoring, consensus regimens and proposed clinical trials. Clin Exp Immunol 1995; 101 (suppl 1): 29-34.